Abstract
Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of triglyceride-rich lipoproteins (TRLPs), including very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL), with no change or a reduction in low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Serum triglycerides and IDL are risk factors for vascular disease in dialysis patients, whereas LDL is not. The principal cause of the increase in TRLPs is decreased removal, not increased synthesis. The clearance defect arises from a reduction in specific lipoprotein receptors, decreases in the activity of lipases, and increased levels of low-molecular weight apolipoproteins that inhibit the interaction between TRLPs and both the receptors and the lipases that catabolize them. VLDL from dialysis patients is structurally abnormal and is not metabolized at a normal rate by lipoprotein lipase (LPL).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 779-781 |
| Number of pages | 3 |
| Journal | Kidney International |
| Volume | 72 |
| Issue number | 7 |
| DOIs | |
| State | Published - Oct 2007 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance. / Kaysen, George.
In: Kidney International, Vol. 72, No. 7, 10.2007, p. 779-781.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance
AU - Kaysen, George
PY - 2007/10
Y1 - 2007/10
N2 - Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of triglyceride-rich lipoproteins (TRLPs), including very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL), with no change or a reduction in low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Serum triglycerides and IDL are risk factors for vascular disease in dialysis patients, whereas LDL is not. The principal cause of the increase in TRLPs is decreased removal, not increased synthesis. The clearance defect arises from a reduction in specific lipoprotein receptors, decreases in the activity of lipases, and increased levels of low-molecular weight apolipoproteins that inhibit the interaction between TRLPs and both the receptors and the lipases that catabolize them. VLDL from dialysis patients is structurally abnormal and is not metabolized at a normal rate by lipoprotein lipase (LPL).
AB - Chronic kidney disease (CKD) is associated with dyslipidemia, characterized by increased levels of triglyceride-rich lipoproteins (TRLPs), including very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL), with no change or a reduction in low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Serum triglycerides and IDL are risk factors for vascular disease in dialysis patients, whereas LDL is not. The principal cause of the increase in TRLPs is decreased removal, not increased synthesis. The clearance defect arises from a reduction in specific lipoprotein receptors, decreases in the activity of lipases, and increased levels of low-molecular weight apolipoproteins that inhibit the interaction between TRLPs and both the receptors and the lipases that catabolize them. VLDL from dialysis patients is structurally abnormal and is not metabolized at a normal rate by lipoprotein lipase (LPL).
UR - http://www.scopus.com/inward/record.url?scp=34648837114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34648837114&partnerID=8YFLogxK
U2 - 10.1038/sj.ki.5002478
DO - 10.1038/sj.ki.5002478
M3 - Article
C2 - 17882238
AN - SCOPUS:34648837114
VL - 72
SP - 779
EP - 781
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 7
ER -